Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Chemother Pharmacol ; 71(1): 175-82, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23064956

ABSTRACT

The American Society of Clinical Oncology recently published a Clinical Practice Guideline entitled "Appropriate Chemotherapy Dosing for Obesity Adult Patients with Cancer." The panel recommended that full weight (actual weight)-based cytotoxic chemotherapy doses are used to treat obese patients with cancer, particularly when the goal of treatment is cure. However, no study has examined dosage calculation methods used for obese cancer patients in Japan. Here, we retrospectively studied the relationships between chemotherapy dose intensity, the occurrence of adverse events, and treatment outcomes in obese patients undergoing chemotherapy. Patients were divided into two groups: the actual BW group (BWg) was composed of patients receiving dosage amounts calculated using their actual BW (n = 64), and the ideal BWg was composed of patients receiving dosage amounts calculated using their ideal BW (n = 41). There were significant differences in the incidence of Grade 3/4 hematological toxicity in the actual and ideal BWg in solid tumor patients, but not in patients with hematological malignancies. In solid tumor patients with ≥30 body mass index (BMI), the incidence of Grade 3/4 hematological toxicity was significantly lower in the ideal BWg than in the actual BWg. Particularly, in patients with complications, incidence of Grade 4 hematological toxicity was significantly higher in the actual BWg than in the ideal BWg. These results suggest that the tumor type, degree of obesity, complications, and choice of chemotherapy regimen should be considered when determining chemotherapy dosage for obese patients.


Subject(s)
Antineoplastic Agents/therapeutic use , Hematologic Neoplasms/drug therapy , Neoplasms/drug therapy , Obesity/complications , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Body Surface Area , Body Weight , Dose-Response Relationship, Drug , Drug Dosage Calculations , Female , Hematologic Neoplasms/pathology , Humans , Japan , Male , Middle Aged , Neoplasms/pathology , Retrospective Studies
2.
Food Chem Toxicol ; 49(4): 722-6, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21112368

ABSTRACT

Lactobacillus brevis KB290 (KB290), a plant-derived probiotic lactic acid bacterium, improves gut health and stimulates immune function. Here we extensively investigated the teratogenicity of KB290 in rats and rabbits. We observed no adverse maternal or fetal effects and concluded that the no observable adverse effect level for maternal general toxicity, maintenance of pregnancy, and teratogenicity should be ≥ 10(10) cfu/kg/day. Our results suggest that KB290 would be safe for pregnant females and their offspring.


Subject(s)
Levilactobacillus brevis , Maternal Exposure , Probiotics , Teratogens , Animals , Female , Male , Pregnancy , Rabbits , Rats
3.
Food Chem Toxicol ; 47(10): 2450-3, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19583990

ABSTRACT

Lactobacillus brevis KB290 (KB290), a plant-derived probiotic lactic acid bacterium, reportedly improves gut health and stimulates immune function. Here we extensively investigated the geno-, acute, subacute, and subchronic toxicity of KB290 and its bacterial translocation potential. KB290 was non-mutagenic in the bacterial reverse mutation assay by the preincubation method. In the single oral dose toxicity test, KB290 at 10(9) cfu/ml was nontoxic at maximum capacity (20 ml/kg). When 10(8), 10(9), or 10(10) cfu/kg was administered daily to rats by gavage for 2 weeks (subacute assay), we observed no clear treatment-related effect and no evidence of bacterial translocation from the gastrointestinal tract. When it was administered for 13 weeks (subchronic assay), we again observed no clear treatment-related effect and no significant toxicological effect. Based on those results, we consider 10(10) cfu/kg per day, the highest dose tested, to be the no observed adverse effect level (NOAEL). These results suggest that KB290 is safe for human consumption.


Subject(s)
Levilactobacillus brevis/physiology , Probiotics/toxicity , Toxicity Tests/methods , Administration, Oral , Animals , Bacterial Translocation/drug effects , Blood Chemical Analysis , Female , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/microbiology , Humans , Longevity/drug effects , Male , Mutation/drug effects , Rats , Rats, Sprague-Dawley , Risk Assessment , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics , Weight Gain/drug effects
4.
Int J Legal Med ; 116(4): 207-11, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12185490

ABSTRACT

The systemic distribution of kerosene components in blood and tissues was analysed in rats following dermal exposure. Four types of trimethylbenzenes (TMBs) and aliphatic hydrocarbons (AHCs) with carbon numbers 9-16 (C(9)-C(16)) were analysed as major kerosene components by capillary gas chromatography/mass spectrometry (GC/MS). The kerosene components were detected in blood and all tissues after a small piece of cotton soaked with kerosene was applied to the abdominal skin. The amounts of TMBs detected were higher than those of AHCs. Greater increases in TMB levels were found in adipose tissue in an exposure duration-dependent manner. The amounts of TMBs detected were only at trace levels following post-mortem dermal exposure to kerosene. These findings suggest that kerosene components were absorbed percutaneously and distributed to various organs via the blood circulation. Post-mortem or ante-mortem exposure to kerosene could be distinguished when the exposure duration was relatively long. Adipose tissue would seem to be the most useful for estimating the degree of kerosene exposure.


Subject(s)
Hydrocarbons/pharmacokinetics , Kerosene/analysis , Skin Absorption , Animals , Gas Chromatography-Mass Spectrometry , Hydrocarbons/analysis , Male , Rats , Rats, Wistar , Tissue Distribution
5.
Nature ; 410(6831): 908-10, 2001 Apr 19.
Article in English | MEDLINE | ID: mdl-11309610

ABSTRACT

The application of a sufficiently strong magnetic field to a superconductor will, in general, destroy the superconducting state. Two mechanisms are responsible for this. The first is the Zeeman effect, which breaks apart the paired electrons if they are in a spin-singlet (but not a spin-triplet) state. The second is the so-called 'orbital' effect, whereby the vortices penetrate into the superconductors and the energy gain due to the formation of the paired electrons is lost. For the case of layered, two-dimensional superconductors, such as the high-Tc copper oxides, the orbital effect is reduced when the applied magnetic field is parallel to the conducting layers. Here we report resistance and magnetic-torque experiments on single crystals of the quasi-two-dimensional organic conductor lambda-(BETS)2FeCl4, where BETS is bis(ethylenedithio)tetraselenafulvalene. We find that for magnetic fields applied exactly parallel to the conducting layers of the crystals, superconductivity is induced for fields above 17 T at a temperature of 0.1 K. The resulting phase diagram indicates that the transition temperature increases with magnetic field, that is, the superconducting state is further stabilized with magnetic field.

6.
Jpn J Pharmacol ; 83(4): 355-8, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11001184

ABSTRACT

The term for re-entrainment to a new light-dark cycle in streptozotocin (STZ)-induced diabetic rats was significantly longer than that in control rats. In STZ-induced diabetic rats, the same level of phase delay in the suprachiasmatic nucleus neuronal firing rhythm was observed in control rats after glutamate application. Therefore, 5-HT function in the hypothalamus is thought to be decreased in STZ-induced diabetic rats. These results suggest that postsynaptic neuronal function is still maintained in the suprachiasmatic nucleus of STZ-induced diabetic rats. Therefore, 5-HT mechanisms may play an important role in the maintenance of this function.


Subject(s)
Brain/metabolism , Circadian Rhythm/physiology , Diabetes Mellitus, Experimental/metabolism , Motor Activity/physiology , Suprachiasmatic Nucleus/metabolism , 5-Hydroxytryptophan/metabolism , Animals , Circadian Rhythm/drug effects , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/physiopathology , Glutamic Acid/pharmacology , Hydroxyindoleacetic Acid/metabolism , Male , Rats , Rats, Wistar , Serotonin/metabolism , Streptozocin , Suprachiasmatic Nucleus/drug effects , Suprachiasmatic Nucleus/physiopathology
7.
Pediatr Res ; 39(2): 281-6, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8825801

ABSTRACT

Suckling (12-d-old) rats that were fasted for 15 h received epidermal growth factor (EGF) s.c. (0.5 and 1.0 microgram per rat, i.e. approximately 2 and 4 micrograms/100 g of body weight), together with motility markers 51Cr-EDTA or Poly R-478, and were killed 45 min later. Counts were measured separately in the stomach and the small intestine, which was divided into 12 segments. Administration of EGF delayed gastric emptying. In controls, the stomach contained 26.1 +/- 1.6% (mean +/- SEM); in EGF-treated rats the stomach contained 75.9 +/- 10.2% and 75.7 +/- 2.5% of the total 51Cr-EDTA counts given. EGF had the maximum effect (1.0 microgram) when given simultaneously with 51Cr-EDTA. Significant, but lower, effects of EGF were seen with the administration of EGF preceded by 10 min or followed by 10 and 20 min with the administration of 51Cr-EDTA (65.8 +/- 5.8%, 60.0 +/- 6.4%, and 54.1 +/- 4.2%, respectively). Small intestinal transit was also delayed. Administration of anti-EGF antiserum did not affect gastric emptying, but accelerated small intestinal transit as determined 30 min after administration of 51Cr-EDTA. These studies are the first to demonstrate the effect of EGF on gastrointestinal motility in vivo in suckling mammals.


Subject(s)
Epidermal Growth Factor/pharmacology , Gastric Emptying/drug effects , Intestine, Small/drug effects , Animals , Biomarkers , Chromium , Edetic Acid/metabolism , Epidermal Growth Factor/immunology , Gastrointestinal Motility/drug effects , Immune Sera , Rats , Rats, Sprague-Dawley
8.
Carbohydr Res ; 232(1): 151-9, 1992 Jul 20.
Article in English | MEDLINE | ID: mdl-1423346

ABSTRACT

Six oligosaccharides were first formed from lactitol by a transgalactosylation reaction catalyzed by Aspergillus oryzae beta-D-galactosidase. From the results of methylation analysis, MS, and 1H- and 13C-NMR studies, it was concluded that these oligosaccharides are O-beta-D-galactopyranosyl-(1----4)-O-beta-D-galactopyranosyl-(1----4)-D- glucitol, O-beta-D-galactopyranosyl-(1----3)-O-beta-D-galactopyranosyl-(1----4)-D- glucitol, O-beta-D-galactopyranosyl-(1----4)-[O-beta-D-galactopyranosyl-(1----6)]- D- glucitol, O-beta-D-galactopyranosyl-(1----6)-O-beta-D-galactopyranosyl-(1---4)- glucitol, O-beta-D-galactopyranosyl-(1----4)-[O-beta-D-galactopyranosyl- (1----5)]-D-glucitol, and O-beta-D-galactopyranosyl-(1----4)-[O-beta-D-galactopyranosyl-(1----1)]- D-glucitol. The last three are newly observed oligosaccharides.


Subject(s)
Aspergillus oryzae/enzymology , Oligosaccharides/biosynthesis , Sugar Alcohols/chemistry , beta-Galactosidase/chemistry , Aspergillus oryzae/chemistry , Carbohydrate Sequence , Catalysis , Glycosylation , Molecular Sequence Data , Oligosaccharides/chemistry , Oligosaccharides/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...